Study Summary
Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia.
Interested in this trial?
Submit an InquiryInterventions
IM19 CAR-TBIOLOGICAL
T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
fludarabine and cyclophosphamideDRUG
Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Hebei Yanda Ludaopei Hospital | Beijing | China |